Cargando…

Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)

Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Galeotti, Caroline, Kaveri, Srini V, Bayry, Jagadeesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565103/
https://www.ncbi.nlm.nih.gov/pubmed/33088506
http://dx.doi.org/10.1002/cti2.1198
_version_ 1783595863139942400
author Galeotti, Caroline
Kaveri, Srini V
Bayry, Jagadeesh
author_facet Galeotti, Caroline
Kaveri, Srini V
Bayry, Jagadeesh
author_sort Galeotti, Caroline
collection PubMed
description Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al. [Image: see text]
format Online
Article
Text
id pubmed-7565103
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75651032020-10-20 Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19) Galeotti, Caroline Kaveri, Srini V Bayry, Jagadeesh Clin Transl Immunology News & Commentary Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al. [Image: see text] John Wiley and Sons Inc. 2020-10-16 /pmc/articles/PMC7565103/ /pubmed/33088506 http://dx.doi.org/10.1002/cti2.1198 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Commentary
Galeotti, Caroline
Kaveri, Srini V
Bayry, Jagadeesh
Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title_full Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title_fullStr Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title_full_unstemmed Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title_short Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
title_sort intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (covid‐19)
topic News & Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565103/
https://www.ncbi.nlm.nih.gov/pubmed/33088506
http://dx.doi.org/10.1002/cti2.1198
work_keys_str_mv AT galeotticaroline intravenousimmunoglobulinimmunotherapyforcoronavirusdisease19covid19
AT kaverisriniv intravenousimmunoglobulinimmunotherapyforcoronavirusdisease19covid19
AT bayryjagadeesh intravenousimmunoglobulinimmunotherapyforcoronavirusdisease19covid19